IRADIMED CORP Faces Nasdaq Listing Scrutiny
Ticker: IRMD · Form: 8-K · Filed: Jun 7, 2024 · CIK: 1325618
Sentiment: neutral
Topics: listing-standards, delisting-risk, compliance
Related Tickers: IRMD
TL;DR
IRADIMED CORP might get kicked off Nasdaq - need to watch this.
AI Summary
On June 5, 2024, IRADIMED CORP filed an 8-K report indicating a potential delisting or failure to meet continued listing standards. The company is addressing issues related to its listing on the Nasdaq Stock Market, though specific details of the non-compliance are not fully elaborated in this initial filing.
Why It Matters
This filing signals potential challenges for IRADIMED CORP's stock trading on the Nasdaq, which could impact investor confidence and liquidity.
Risk Assessment
Risk Level: medium — The filing directly addresses potential delisting, which poses a significant risk to the company's stock.
Key Players & Entities
- IRADIMED CORP (company) — Registrant
- Nasdaq Stock Market (company) — Exchange where the company is listed
- June 5, 2024 (date) — Date of earliest event reported
FAQ
What specific continued listing rule or standard has IRADIMED CORP failed to satisfy?
The filing states that the company received a notice regarding failure to satisfy a continued listing rule or standard, but the specific rule is not detailed in this 8-K.
What is the potential consequence of failing to meet the listing standards?
The consequence is a potential delisting from the Nasdaq Stock Market.
Has IRADIMED CORP requested a hearing with the Nasdaq Stock Market?
The filing does not explicitly state whether a hearing has been requested, but such filings typically precede or accompany such requests.
What is the company's primary business?
IRADIMED CORP is involved in the business of Surgical & Medical Instruments & Apparatus, as indicated by its SIC code 3841.
When was this 8-K filing submitted?
This 8-K filing was submitted on June 7, 2024.
Filing Stats: 640 words · 3 min read · ~2 pages · Grade level 11.2 · Accepted 2024-06-07 08:30:29
Key Financial Figures
- $0.0001 — h registered: Common stock, par value $0.0001 IRMD NASDAQ Capital Market Item 3
Filing Documents
- irmd-20240605x8k.htm (8-K) — 36KB
- irmd-20240605xex99d1.htm (EX-99.1) — 11KB
- irmd-20240605xex99d1001.jpg (GRAPHIC) — 10KB
- 0001558370-24-008988.txt ( ) — 180KB
- irmd-20240605.xsd (EX-101.SCH) — 3KB
- irmd-20240605_lab.xml (EX-101.LAB) — 15KB
- irmd-20240605_pre.xml (EX-101.PRE) — 10KB
- irmd-20240605x8k_htm.xml (XML) — 5KB
01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard Transfer of Listing
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard Transfer of Listing. On June 5, 2024, IRADIMED CORPORATION, a Delaware corporation (the " Company "), received approval from the Listing Qualifications Department of The Nasdaq Stock Market LLC (" Nasdaq ") to transfer the listing of the Company's common stock from the Nasdaq Capital Market to the Nasdaq Global Market, effective as of the open of business on June 14, 2024. The Company's common stock will continue to trade under the symbol "IRMD". The Nasdaq Global Market operates in substantially the same manner as the Nasdaq Capital Market and listed companies must meet certain financial requirements and comply with Nasdaq's corporate governance requirements.
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On June 7, 2024, the Company issued a press release announcing that effective on the opening of business on June 14, 2024, the Company's common stock will be uplisted to the Nasdaq Global Market. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act ") or otherwise subject to the liabilities of that Section. Furthermore, such information, including Exhibit 99.1, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by the registrant on June 7, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IRADIMED CORPORATION Date: June 7, 2024 By: /s/John Glenn Name: John Glenn Title: Chief Financial Officer